NKTR-214 CR data at SITC suggest advantage over SOC

Updated Phase I/II data presented Friday for NKTR-214 from Nektar Therapeutics (NASDAQ:NKTR) plus Opdivo nivolumab to treat previously untreated patients with metastatic stage IV melanoma showed an objective response rate (ORR) that included more patients who had a complete response, potentially giving it an edge over the current standard-of-care first-line combination if the results hold up in a Phase III trial.

Nektar reported the update at the Society for Immunotherapy of Cancer meeting in Washington...